JPY 463.0
(2.89%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 37.74 Million JPY | -84.37% |
2022 | 241.49 Million JPY | -57.68% |
2021 | 570.6 Million JPY | 751.38% |
2020 | 67.02 Million JPY | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | -7.94 Million JPY | -227.81% |
2024 Q1 | 6.21 Million JPY | -75.78% |
2023 Q4 | 25.66 Million JPY | 928.78% |
2023 FY | 37.74 Million JPY | -84.37% |
2023 Q3 | 2.49 Million JPY | -55.94% |
2023 Q2 | 5.66 Million JPY | 44.54% |
2023 Q1 | 3.91 Million JPY | -69.63% |
2022 FY | 241.49 Million JPY | -57.68% |
2022 Q4 | 12.9 Million JPY | 181.26% |
2022 Q3 | -15.87 Million JPY | 0.0% |
2021 FY | 570.6 Million JPY | 751.38% |
2020 FY | 67.02 Million JPY | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Pharma Foods International Co., Ltd. | 48.75 Billion JPY | 99.923% |
Takeda Pharmaceutical Company Limited | 2184.96 Billion JPY | 99.998% |
Sumitomo Pharma Co., Ltd. | 187.98 Billion JPY | 99.98% |
Shionogi & Co., Ltd. | 369.08 Billion JPY | 99.99% |
Wakamoto Pharmaceutical Co.,Ltd. | 3.54 Billion JPY | 98.934% |
Nippon Shinyaku Co., Ltd. | 97.01 Billion JPY | 99.961% |
Kaken Pharmaceutical Co., Ltd. | 38.22 Billion JPY | 99.901% |
Eisai Co., Ltd. | 586.41 Billion JPY | 99.994% |
Morishita Jintan Co., Ltd. | 5.99 Billion JPY | 99.371% |
Hisamitsu Pharmaceutical Co., Inc. | 78.97 Billion JPY | 99.952% |
Mochida Pharmaceutical Co., Ltd. | 52.07 Billion JPY | 99.928% |
Fuso Pharmaceutical Industries,Ltd. | 13.51 Billion JPY | 99.721% |
Nippon Chemiphar Co., Ltd. | 7.73 Billion JPY | 99.512% |
Tsumura & Co. | 68.81 Billion JPY | 99.945% |
Kissei Pharmaceutical Co., Ltd. | 37.34 Billion JPY | 99.899% |
Torii Pharmaceutical Co., Ltd. | 24.79 Billion JPY | 99.848% |
Towa Pharmaceutical Co., Ltd. | 81.38 Billion JPY | 99.954% |
Fuji Pharma Co., Ltd. | 16.51 Billion JPY | 99.771% |
Zeria Pharmaceutical Co., Ltd. | 50.18 Billion JPY | 99.925% |
KYORIN Holdings, Inc. | 51.4 Billion JPY | 99.927% |
Taiko Pharmaceutical Co.,Ltd. | 1.07 Billion JPY | 96.502% |
Daito Pharmaceutical Co.,Ltd. | 9.83 Billion JPY | 99.616% |
SymBio Pharmaceuticals Limited | 4.41 Billion JPY | 99.144% |
MedRx Co., Ltd | 26 Million JPY | -45.169% |
Mizuho Medy Co.,Ltd. | 8.02 Billion JPY | 99.53% |
Solasia Pharma K.K. | 337 Million JPY | 88.8% |
Modalis Therapeutics Corporation | -731 Thousand JPY | 5263.338% |
ASKA Pharmaceutical Holdings Co.,Ltd. | 30.66 Billion JPY | 99.877% |
Sawai Group Holdings Co., Ltd. | 54.31 Billion JPY | 99.931% |
Toho Holdings Co., Ltd. | 112.98 Billion JPY | 99.967% |
Koa Shoji Holdings Co.,Ltd. | 6.63 Billion JPY | 99.432% |